Invicta Medical Technologies Limited operates a network of diagnostic centres providing pathology, radiology, and health check-up services across Telangana, Andhra Pradesh and Karnataka. The company earns revenue by offering diagnostic tests, imaging services, and wellness packages to hospitals, clinicians, corporate clients, and individual patients. Its services are used for preventive care, disease detection, and clinical diagnosis.

The Company is led by Promoter, i.e., DR. KETAN JAYANTILAL JAIN, DR. SANKET VINOD JAIN, ROHIT PRAKASH SRIVASTAVA, BADAL KAILASH NAREDI AND JAYESH PRAKASH JAIN

The Revenues from operations for the Period ended on Sep 30 2025 and Fiscals ended on Mar 31, 2025, 2024 and  were â‚¹ 1,707.96 Lakh, ₹ 3,018.14 Lakh, and ₹ 1,589.82 Lakh, The EBITDA for the Period ended on Sep 30 2025,and Fiscals ended on Mar 31, 2025, 2024 and were â‚¹ 676.50 Lakh, ₹ 919.89 Lakh, and  ₹ 708.68 Lakh,The Profit after Tax for the Period ended on Sep 30 2025, and Fiscals ended on Mar 31, 2025, 2024 and were were â‚¹ 408.41 Lakh, ₹ 492.95 Lakh, and ₹ 380.54 Lakh, respectively. This indicates a steady growth in financial performance.

The Company Key Performance Indicates the pre-issue EPS of â‚¹5.86 and post-issue EPS of ₹3.92 for FY25. The pre-issue P/E ratio is 14.51x,while the post-issue P/E ratio is 21.68x against the Industry P/E ratio is 53.3x The company's ROE for FY25 is 44.28% and RoNW is 36.25% The Annualised EPS is ₹6.50x and P/E is 13.08x. These metrics suggest that the IPO is Fully priced.

The Grey Market Premium (GMP) of Invicta Diagnostic showing listing gains of  0%.Given the company's financial performance and the valuation of the IPO, we recommend  Investors to Avoid to the Invicta Diagnostic Limited IPO for Listing gain or Long Term Purposes.